Yinnuo Pharmaceutical's IPO and the "full circulation" of domestically unlisted shares have been approved by the China Securities Regulatory Commission.

The International Cooperation Department of the China Securities Regulatory Commission issued a filing notice regarding the overseas issuance and listing of Guangzhou Yinnuo Pharmaceutical Group Co., Ltd. and the "full circulation" of domestically unlisted shares. The company plans to issue a maximum of 69,043,500 shares of overseas listed common stock and list them on the Hong Kong Stock Exchange. 45 shareholders of the company intend to convert a total of 383,729,000 domestically unlisted shares into overseas listed shares and have them listed for circulation on the Hong Kong Stock Exchange.